Current Report Filing (8-k)
May 15 2017 - 5:44PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(
d
)
of
The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 15, 2017
Interpace
Diagnostics Group, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-24249
|
|
22-2919486
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
Morris
Corporate Center 1, Building A
300
Interpace Parkway
Parsippany,
NJ 07054
(Address,
including zip code, of Principal Executive Offices)
(855)
776-6419
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
[ ]
|
Emerging
growth company
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
2.02 Results of Operations and Financial Condition
On
May 15, 2017, Interpace Diagnostics Group, Inc. (the “Company”) issued a press release announcing its results of operations
and financial condition for the quarter ended March 31, 2017. The full text of the press release is set forth as Exhibit 99.1
attached hereto and is incorporated herein by reference.
The
information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)
or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any registration
statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated
in such filing.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
99.1
|
|
Press
Release dated May 15, 2017 (furnished pursuant to Item 2.02).
|
Exhibit
Number
|
|
Description
|
|
|
|
99.1*
|
|
Press
Release dated May 15, 2017.
|
*
Filed herewith
signatureS
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Interpace
Diagnostics Group, Inc.
|
|
|
|
Date:
May 15, 2017
|
By:
|
/s/
Jack E. Stover
|
|
Name:
|
Jack
E. Stover
|
|
Title:
|
President
and Chief Executive Officer
|
EXHIBIT
INDEX
Exhibit
Number
|
|
Description
|
|
|
|
99.1*
|
|
Press
Release dated May 15, 2017.
|
*
Filed herewith
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Sep 2023 to Sep 2024